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Background
Raltegravir is the first in the new class of integrase inhibi-
tors. In treatment-experienced patients with advanced
HIV disease, raltegravir in combination with optimized
background therapy (OBT) showed superior efficacy com-
pared with placebo with OBT at week 16, 24, and 48. This
research focuses on the cost-effectiveness of raltegravir
from the National Health Service (NHS) perspective.
Methods
We developed a decision model to estimate the long-term
(over 30 years) clinical and economic outcomes associ-
ated with using raltegravir in treatment-experienced HIV
patients in the UK (UK) for 5 years using the NHS perspec-
tive. The model stratifies HIV-1 infected persons into sev-
eral heath states according to their HIV-RNA level, CD4-
lymphocyte cell count, and history of opportunistic infec-
tions (OI). Each health state is associated with a distinct
set of costs (for prophylaxis, testing, and treatment of
complications) and quality of life (utility) scores. Inputs
for the model were obtained from clinical trials, pub-
lished studies, and database analysis. Output included
number and type of OI, projected life expectancy, quality-
adjusted life expectancy, lifetime direct costs, and incre-
mental cost-effectiveness ratios (ICER). The ICERs were
expressed in 2007 British pounds per quality-adjusted life
year (QALY) gained (£/QALY). Both future costs and
QALYs were discounted to the present value at 3.5% per
year. Extensive sensitivity and subgroup analyses were
conducted.
Summary of results
Projected model outcomes were generally within the
range of values reported in the literature. Compared with
OBT, raltegravir (as an add-on to OBT) increased dis-
counted QALYs by 2.19 years at an additional discounted
cost of £35,984, resulting in an ICER of £16,431/QALY.
The results were sensitive to changes in utility weights,
treatment duration, mortality rates, health utility weights,
analytic time horizon, cost of OBT, cost of raltegravir, inci-
dence of OIs, and discount rate. However, in most scenar-
ios assessed, the ICER was below £20,000.
Conclusion
Use of raltegravir is projected to result in substantial qual-
ity-adjusted survival benefits and is cost-effective in treat-
ment-experienced patients in the UK when compared
with current standard of care.
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